{"id":"glucocorticoids-reduced-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Osteoporosis"},{"rate":null,"effect":"Immunosuppression/increased infection risk"},{"rate":null,"effect":"Adrenal suppression"},{"rate":null,"effect":"Mood changes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glucocorticoids are corticosteroids that work by entering cells and binding to intracellular glucocorticoid receptors, which then translocate to the nucleus and regulate transcription of anti-inflammatory and immunosuppressive genes. The reduced-dose formulation aims to maintain therapeutic efficacy while minimizing systemic adverse effects associated with standard glucocorticoid dosing. This approach is being investigated to improve the risk-benefit profile in chronic inflammatory and autoimmune conditions.","oneSentence":"Reduced-dose glucocorticoids suppress immune and inflammatory responses by binding to glucocorticoid receptors and modulating gene expression.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:06.151Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune conditions (specific indication under investigation in phase 3 trial)"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46029,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Glucocorticoids [Reduced Dose]","genericName":"Glucocorticoids [Reduced Dose]","companyName":"University of Pennsylvania","companyId":"university-of-pennsylvania","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Reduced-dose glucocorticoids suppress immune and inflammatory responses by binding to glucocorticoid receptors and modulating gene expression. Used for Inflammatory and autoimmune conditions (specific indication under investigation in phase 3 trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}